This was the stock's second consecutive day of losses.

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

The stock's fall snapped a four-day winning streak.

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.

Learn more about whether Vertex, Inc. or Workiva Inc. is a better investment based on AAII's A+ Investor grades, which ...

Shares of Vertex Pharmaceuticals gained about 6% Friday morning, after the pharmaceutical company won U.S. approval for the ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Learn more about whether Q2 Holdings, Inc. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...